Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Core Insights - VolitionRx Limited has initiated a clinical study to evaluate its Nu.Q® Cancer technology for differentiating between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer [1][5] - The study, in collaboration with National Taiwan University Hospital, aims to enroll 500 patients and is expected to be completed by the end of 2025 [1][2] - Previous studies indicate that the Nu.Q® Cancer test can accurately identify malignant nodules with high sensitivity, which could lead to its inclusion in national lung cancer screening programs [4][5] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection of diseases [8][9] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers [9] - Volition's research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [9] Industry Context - Lung cancer is a leading cause of cancer-related deaths globally, and LDCT is recognized as the gold standard for lung cancer screening [3] - The high sensitivity of LDCT can lead to false positives and unnecessary invasive procedures for patients with benign nodules, highlighting the need for more accurate diagnostic tools [3][6] - A blood-based test that can distinguish between cancerous and non-cancerous nodules would significantly enhance clinical practice and lung cancer screening programs [7]